Ming Bioventures
26
20M
23
4.33
6
0.12
1
- Areas of investment
Summary
Ming Bioventures appeared to be the VC, which was created in 2018. The main office of represented VC is situated in the Suzhou. The fund was located in Asia if to be more exact in China.
The fund is constantly included in 2-6 deals per year. Comparing to the other companies, this Ming Bioventures performs on 4 percentage points more the average number of lead investments. The important activity for fund was in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars. The increased amount of exits for fund were in 2019. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Ming Bioventures, startups are often financed by Sequoia Capital China, SBCVC. The meaningful sponsors for the fund in investment in the same round are Yingqi Investment, Xiamen Changrong Investment Management, Tencent Holdings.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most successful fund investment fields, there are Medical Device, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight SyMap Medical, Viva Biotech.
Investments analytics
Analytics
- Total investments
- 26
- Lead investments
- 6
- Exits
- 1
- Rounds per year
- 4.33
- Follow on index
- 0.12
- Investments by industry
- Biotechnology (16)
- Health Care (14)
- Medical (11)
- Biopharma (7)
- Medical Device (6) Show 10 more
- Investments by region
-
- China (20)
- United States (5)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 28M
- Group Appearance index
- 0.88
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Abogen Biosciences | 01 Jul 2020 | Biotechnology, Life Science | Seed | Jiangsu, Gusu District, China | |
| Redbud Medicine | 23 Aug 2022 | Health Care, Medical | Early Stage Venture | 10M | Beijing, Haidian, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.